Huron Managing Director David Gilman offers insight into value-based drug pricing and pharmaceutical innovation in the recent article, Is Value-Based Drug Pricing Compatible with Pharma Innovation?
The article was originally featured in NEJM Catalyst, an online publication from the New England Journal of Medicine.
With prescription drugs per-capita spending expected to rise 6.3 percent by 2024, the pharmaceutical industry is pressed to find solutions that are both effective and affordable. One proposed remedy to this industry problem is value-based pricing, tying the price of a drug directly to its value to patients.
The article addresses:
- Challenges to the fundamentals of drug pricing
- The intent of value-based pricing
- The future of value-based drug pricing
Click here to read the article.